In the alternative pathway, C3b binds to Factor B. Factor D releases Factor Ba from Factor B bound to C3b. The complex of C3b (2)Bb is a protease which cleaves C5 into C5b and C5a. C5 convertase is ...

The complement pathway is a part of the innate immune system and C3 activation is required for the classical complement pathway, the alternative complement pathway, and the lectin pathway.

Plus, it has to be taken every day subcutaneously. On the other hand, DNTH103 avoids targeting the lectin [C5 inhibition seen here] and alternative pathways [c3a, c35a and other pathways seen here].

The lectin pathway is homologous to the classical pathway, but with the opsonin, mannose-binding lectin (MBL) and ficolins, instead of C1q. The FDA has now approved seven indications for ...

ANX007 is an investigational monoclonal antibody antigen-binding fragment for the treatment of patients with complement-mediated neurodegenerative ophthalmic diseases. Formulated for intravitreal ...

In addition to its lectin pathway inhibitors, the company is advancing its development of antibodies and small-molecule inhibitors against MASP-3 to block activation of the alternative pathway.

Immunoglobulin A (IgA) nephropathy is the most prevalent glomerulonephritis worldwide that does not have a specific treatment. Its pathogenesis is complex and not well understood, but there is ...